TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21114478
Drug: Low-dose treatment
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose treatment (group B)
Study: 21114478
Drug: Intermittent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent treatment (group C)
Study: 16326295
Drug: Magnesium group
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium group (2.5 g magnesium sulphate infusion intraoperatively over 30 minutes)
Study: 16326295
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (normal saline solution)
Study: 11119180
Drug: Cue-dose training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cue-dose training (CD)
Study: 8327595
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin (0.035 IU/kg body weight)
Study: 29534874
Drug: VT‐1161 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: VT‐1161 150 mg once daily for 7 days, then 150 mg once weekly for 11 weeks, followed by a once‐weekly dose of placebo for 12 weeks
Study: 29534874
Drug: VT‐1161 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: VT‐1161 300 mg once daily for 7 days, then 300 mg once weekly for 11 weeks, followed by a once‐weekly dose of placebo for 12 weeks
Study: 29534874
Drug: VT‐1161 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: VT‐1161 150 mg once daily for 7 days, then 150 mg once weekly for 23 weeks
Study: 29534874
Drug: VT‐1161 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: VT‐1161 300 mg once daily for 7 days, then 300 mg once weekly for 23 weeks
Study: 27234671
Drug: Once-weekly teriparatide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly teriparatide therapy for 72 weeks
Study: 23291317
Drug: Tomato juice
Normalized name: TOMATO JUICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato juice administered during and after exercise for over a 2-month period
Study: 14568892
Drug: Cerivastatin (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin (0.3 mg)
Study: 31652452
Drug: PHOX2B rs28647582
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHOX2B rs28647582 T>C polymorphism (TC/CC genotypes)
Study: 24974817
Drug: AREDS supplements
Normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AREDS supplements (placebo, antioxidants (vitamin C, vitamin E, β-carotene), zinc, or a combination)
Study: 24974817
Drug: AREDS supplements
Normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AREDS supplements
Study: 17187005
Drug: Diane 35
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diane 35 (cyproterone acetate 2 mg with ethinylestradiol 35 µg) for 6 months
Study: 9086582
Drug: T3 (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: T3 (0.2 microgram/kg bolus, 0.4 microgram/kg infusion over 6 hours)
Study: 8412266
Drug: Postoperative cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative cisplatin and vindesine chemotherapy
Study: 30586843
Drug: Cashew nuts
Normalized name: Cashew nuts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cashew nuts (42 g/day)
Study: 23301476
Drug: Auricular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular therapy based on the pattern/syndrome differentiation
Study: 23301476
Drug: Conventional auricular
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional auricular point sticking therapy
Study: 14551489
Drug: Dexamethasone therapy
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone therapy for 4 days
Study: 19713248
Drug: CAPOX (oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAPOX (oxaliplatin 65 mg/m2 i.v. days 1 and 8 and capecitabine 1000 mg/m2 orally b.i.d. days 1-14; q21d)
Study: 19713248
Drug: CAPIRI (irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAPIRI (irinotecan 80 mg/m2 i.v. days 1 and 8 and capecitabine 1000 mg/m2 orally b.i.d. days 1-14; q21d)
Study: 12670840
Drug: Sodium thiosulfate
Normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium thiosulfate (STS) 0.125 mg
Study: 12670840
Drug: Sodium thiosulfate
Normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium thiosulfate (STS) 1.25 mg
Study: 12670840
Drug: Sodium thiosulfate
Normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium thiosulfate (STS) 12.5 mg
Study: 12670840
Drug: Sodium thiosulfate
Normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium thiosulfate (STS) 125 mg
Study: 12670840
Drug: Sodium thiosulfate
Normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium thiosulfate (STS) 1,250 mg
Study: 11772961
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg oral baclofen
Study: 30862500
Drug: Netarsudil ophthalmic
Normalized name: netarsudil ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netarsudil ophthalmic solution 0.02% QD (PM)
Study: 30862500
Drug: Timolol ophthalmic
Normalized name: timolol ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol ophthalmic solution 0.5% BID
Study: 23552589
Drug: Dexmedetomidine 1ug/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1ug/kg administered intravenously over 10 minutes before intubation (group D)
Study: 23552589
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline administered (group C)
Study: 12705062
Drug: Celecoxib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (200 mg daily)
Study: 15579735
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg octreotide long-acting repeatable (LAR) every 4 wk for 16 wk
Study: 15579735
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg octreotide LAR
Study: 11463593
Drug: Low tidal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tidal volume (VT) mechanical ventilation strategy (6 ml/kg)
Study: 2853047
Drug: Rice bran
Normalized name: Rice bran
DrugBank: Rice bran (DB14361)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice bran (17.1 g/d)
Study: 2853047
Drug: Wheat bran
Normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat bran (15.0 g/d)
Study: 29389474
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg rosemary twice daily for one month
Study: 23025690
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (24 IU/dose, given twice daily for 3 days)
Study: 8625660
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (bud), 1,600 micrograms/d
Study: 8625660
Drug: Inhaled budesonide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide, 1,600 micrograms/d, plus oral prednisolone, 5 micrograms/d (bud + pred)
Study: 1428609
Drug: HTR polymer
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTR polymer implant
Study: 1428609
Drug: Control site
Normalized name: SOLO SITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control site (surgically debrided without implant)
Study: 6307772
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ranitidine twice daily
Study: 1853146
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg ranitidine twice daily
Study: 19944452
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with paclitaxel and carboplatin
Study: 28770631
Drug: Dose-matched science
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose-matched science and technology female leadership curriculum
Study: 26603297
Drug: Carboplatin (CBDCA,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (CBDCA, area under the curve = 5) plus pemetrexed (PEM, 500 mg/m²) followed by maintenance pemetrexed (PEM)
Study: 20633419
Drug: DTMS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTMS treatment
Study: 14766684
Drug: 300 mL
Normalized name: HYQVIA 30 GM / 300 ML Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mL clear liquid two hours before surgery
Study: 9692616
Drug: Erythropoietin (Epo)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (Epo) therapy for 8 months
Study: 9692616
Drug: Ketanserin treatment
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin treatment for 14 days
Study: 11772800
Drug: Rofecoxib 50
Normalized name: rofecoxib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 50 mg before surgery
Study: 11772800
Drug: Rofecoxib 50
Normalized name: rofecoxib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 50 mg after surgery
Study: 28074750
Drug: Consultant pharmacist
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consultant pharmacist services with academic detailing, medication monitoring system alerts, and structured recommendations for ADE management
Study: 24742498
Drug: FDC AZI/AML
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC AZI/AML 20/5 mg
Study: 24742498
Drug: FDC AZI/AML
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC AZI/AML 20/2.5 mg
Study: 24742498
Drug: AZI 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZI 20 mg
Study: 24742498
Drug: AML 5
Normalized name: AML-2-23
DrugBank: AML-2-23 (DB17433)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AML 5 mg
Study: 24742498
Drug: AML 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AML 2.5 mg
Study: 19580461
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg per week of risedronate
Study: 19580461
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg per week of risedronate
Study: 19580461
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg per week of risedronate
Study: 19580461
Drug: risedronate (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: risedronate (all doses)
Study: 19580461
Drug: 1 or
Normalized name: G-1 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 or 2 mg/kg per week of risedronate
Study: 19091088
Drug: modified Constraint-Induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified Constraint-Induced Movement Therapy (modified CIMT) for 3 weeks
Study: 15777325
Drug: Progressively loaded
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressively loaded implants
Study: 12501878
Drug: Cefditoren 200
Normalized name: cefditoren 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefditoren 200 mg BID
Study: 12501878
Drug: Cefditoren 400
Normalized name: cefditoren 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefditoren 400 mg BID
Study: 12501879
Drug: Amoxicillin/clavulanate 875/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate 875/125 mg BID
Study: 8551535
Drug: Amoxicillin/clavulanate and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate and Lactobacillus acidophilus
Study: 8551535
Drug: Amoxicillin/clavulanate only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate only
Study: 27250120
Drug: DHA emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA emulsion (60 mg/kg/day)
Study: 21927836
Drug: LCE 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCE 125 mg after LCE 150 mg
Study: 21927836
Drug: LCE 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCE 100 mg
Study: 17452165
Drug: EOB and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: EOB and VE/VCO2 slope combination
Study: 12568481
Drug: Immediate therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate therapy
Study: 9524826
Drug: Sulbactam/cefoperazone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulbactam/cefoperazone (2 g/4 g every 12 hours)
Study: 9524826
Drug: Imipenem (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem (500 mg every 6 hours)
Study: 2504834
Drug: Roxithromycin (RU)
Normalized name: roxithromycin
DrugBank: Roxithromycin (DB00778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin (RU) at a daily dosage of 300 mg
Study: 2504834
Drug: Josamycin (JM)
Normalized name: josamycin
DrugBank: Josamycin (DB01321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Josamycin (JM) at a daily dosage of 1200 mg
Study: 1060748
Drug: Placebo (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (no specific agent mentioned)
Study: 17849380
Drug: Preoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiation therapy with postoperative anastomotic leakage
Study: 12828501
Drug: Zolmitriptan nasal
Normalized name: Zolmitriptan Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan nasal spray 5.0 mg
Study: 12412823
Drug: Zolmitriptan nasal
Normalized name: Zolmitriptan Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan nasal spray 2.5 mg
Study: 12828501
Drug: Zolmitriptan nasal
Normalized name: Zolmitriptan Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan nasal spray 1.0 mg
Study: 12412823
Drug: Zolmitriptan nasal
Normalized name: Zolmitriptan Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan nasal spray 0.5 mg
Study: 8508996
Drug: Nilvadipine 8
Normalized name: nilvadipine 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilvadipine 8 or 16 mg once daily
Study: 3521557
Drug: Topical carbonic
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical carbonic anhydrase inhibitor (aminozolamide) - 50 microL gel application
Study: 25341478
Drug: ARB-H (losartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB-H (losartan 50 mg and hydrochlorothiazide 12.5 mg)
Study: 25341478
Drug: Control (amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (amlodipine 2.5 mg daily)
Study: 25341478
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (including amlodipine 2.5 mg daily)
Study: 19528204
Drug: Rosiglitazone (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (12 weeks treatment)
Study: 17289483
Drug: Dexamethasone (DEX)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DEX) 0.6 mg/kg
Study: 1450496
Drug: Heparin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin alone (group A)
Study: 6541387
Drug: Phenylpropanolamine (PPA)
DrugBank: Phenylpropanolamine (DB00397)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylpropanolamine (PPA) 50 mg p.o. twice daily
Study: 6541387
Drug: Estriol vaginal
Normalized name: estriol Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estriol vaginal suppositories 1 mg daily
Study: 6541387
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with PPA and estriol
Study: 3781985
Drug: Adenosine infusion
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine infusion (70-80 micrograms X kg‐1 X min‐1)
Study: 2188763
Drug: Control saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control saline infusion
Study: 23983593
Drug: 0.5 µg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 µg/kg dexmedetomidine
Study: 23983593
Drug: 0.75 µg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 µg/kg dexmedetomidine
Study: 23983593
Drug: 1.0 µg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 µg/kg dexmedetomidine
Study: 29668397
Drug: LED treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LED treatment
Study: 11093999
Drug: bupivacaine 10
Normalized name: BUPivacaine 100 mg parenteral implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 10 mg + fentanyl 25 microg
Study: 11093999
Drug: bupivacaine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 7.5 mg + fentanyl 25 microg
Study: 11093999
Drug: bupivacaine 5
Normalized name: Sure-Amp BUPivacaine 5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 5 mg + fentanyl 25 microg
Study: 2859924
Drug: low-dose chlorozotocin
Normalized name: chlorozotocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: low-dose chlorozotocin (120 mg/m2)
Study: 2859924
Drug: high-dose chlorozotocin
Normalized name: chlorozotocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: high-dose chlorozotocin (175 mg/m2)
Study: 27569824
Drug: L-carnitine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (3 g/L)
Study: 27569824
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no L-carnitine)
Study: 23519822
Drug: Rehmannia glutinosa
Normalized name: Rehmannia Glutinosa Root
DrugBank: Rehmannia glutinosa root (DB14290)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehmannia glutinosa acteosides (two 200‐mg capsules, bid) and irbesartan (one 150‐mg tablet, qd)
Study: 23519822
Drug: Irbesartan (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (one 150‐mg tablet, qd)
Study: 7520395
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment and control groups
Study: 20386016
Drug: RO5068760 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO5068760 50 mg
Study: 20386016
Drug: RO5068760 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO5068760 100 mg
Study: 20386016
Drug: RO5068760 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO5068760 200 mg
Study: 20386016
Drug: RO5068760 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO5068760 400 mg
Study: 20386016
Drug: RO5068760 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO5068760 600 mg
Study: 20386016
Drug: RO5068760 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO5068760 800 mg
Study: 20386016
Drug: RO5068760 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO5068760 (all doses)
Study: 12897739
Drug: Efalizumab (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efalizumab (0.7 mg/kg conditioning dose followed by 7 weekly doses of 2.0 mg/kg)
Study: 11391843
Drug: Interferon alfa-2a
Normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa-2a monotherapy at a maintenance dose of 9 MIU daily for 12 months
Study: 11391843
Drug: Interferon alfa-2a
Normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa-2a monotherapy
Study: 8855830
Drug: Benfluorex (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benfluorex (150 mg/tablet)
Study: 2210587
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 tablets/day)
Study: 1516390
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml of 2.5 percent cocaine by intratracheal injection (TI) (n = 18)
Study: 1516390
Drug: Bronchoscopic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchoscopic injection of cocaine (BI) (n = 19)
Study: 1516390
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml of 4 percent lidocaine delivered by nebulizer (NEB) (n = 16)
Study: 6231942
Drug: Topical clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clindamycin phosphate (1% solution) twice daily
Study: 6231942
Drug: Benzoyl peroxide
Normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzoyl peroxide (5% gel) twice daily
Study: 6231942
Drug: Benzoyl peroxide
Normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzoyl peroxide (5% gel) in the morning and clindamycin phosphate (1% solution) in the evening
Study: 6231942
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Benzoyl peroxide and clindamycin phosphate)
Study: 30638771
Drug: Structured personal
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured personal care (individualized multifactorial treatment)
Study: 23153661
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of green tea extract 400 mg containing 94% pure EGCG
Study: 19414584
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg twice a day (b.i.d.) for seven doses
Study: 19414584
Drug: Clarithromycin 1000
Normalized name: clarithromycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 1000 mg twice a day (b.i.d.)
Study: 14711556
Drug: Raloxifene (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (180 mg/d)
Study: 11907847
Drug: Betamethasone valerate
Normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone valerate foam (Luxiq) twice a day for four weeks
Study: 9134274
Drug: Imidapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidapril (5 mg daily)
Study: 7701055
Drug: Oxazepam (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxazepam (40 mg)
Study: 16182353
Drug: Oxazepam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxazepam (20 mg)
Study: 29986448
Drug: Shooters with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shooters with BLL ≥ 5 µg/dL
Study: 29986448
Drug: Shooters with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shooters with BLL ≥ 10 µg/dL
Study: 29490680
Drug: Usual medications
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual medications
Study: 21931653
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg per day)
Study: 21931653
Drug: Donepezil (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (single 5 mg dose)